Combination ibrutinib (Ibr) and venetoclax (Ven) for the treatment of mantle cell lymphoma (MCL): Primary endpoint assessment of the phase 2 AIM study.

被引：6
|
作者：
Tam, Constantine Si Lun
Roberts, Andrew Warwick
Anderson, Mary Ann
Dawson, Sarah-Jane
Hicks, Rodney J.
Burbury, Kate
Turner, Gillian
Di Iulio, Juliana
Bressel, Mathias
Westerman, David A.
Agarwal, Rishu
Pott, Christiane
Dreyling, Martin H.
Dawson, Mark A.
Seymour, John Francis
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.7520
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7520
引用
收藏
页数：6
相关论文
共 50 条
  • [31] Phase 2 study of the combination of ibrutinib plus venetoclax in patients with treatment-naive CLL/SLL
    Wierda, William
    Siddiqi, Tanya
    Stevens, Don
    Flinn, Ian
    Ghia, Paolo
    Russell, Kristin
    Eckert, Karl
    Zhou, Cathy
    Ninomoto, Joi
    James, Danelle
    Tam, Constantine
    LEUKEMIA & LYMPHOMA, 2017, 58 : 89 - 90
  • [32] Traverse: A Phase 2, Open-Label, Randomized Study of Acalabrutinib in Combination with Venetoclax and Rituximab in Patients with Treatment-Naive Mantle Cell Lymphoma
    Hawkes, Eliza A.
    Fletcher, Rachel
    Wood, Andrew
    Meyer, Stefanie
    Rule, Simon
    Zhang, Jingyang
    Wang, Michael L.
    BLOOD, 2023, 142
  • [33] Frontline Treatment with Ibrutinib with Rituximab (IR) Combination Is Highly Effective in Elderly (≥65 years) Patients with Mantle Cell Lymphoma (MCL) - Results from a Phase II Trial
    Jain, Preetesh
    Lee, Hun Ju
    Steiner, Raphael Eric
    Hagemeister, F. B.
    Samaniego, Felipe
    Westin, Jason R.
    Nastoupil, Loretta J.
    Ahmed, Sairah
    Iyer, Swaminathan P.
    Romaguera, Jorge Enrique
    Zhao, Shuangtao
    Nomie, Krystle
    Ok, Chi Young
    Kanagal-Shamanna, Rashmi
    Oriabure, Onyeka
    Xu, Guofang
    Zhang, Liang
    Jiang, Changying
    Jung, Dayoung
    Navsaria, Lucy
    Chen, Wendy
    Moghrabi, Omar
    Nizam, Tayyaba
    McClain, Chloe Marie
    Badillo, Maria
    Thirumurthi, Selvi
    Santos, David
    Tang, Guilin
    Patel, Keyur
    Neelapu, Sattva S.
    Wang, Linghua
    Fowler, Nathan H.
    Wang, Michael L.
    BLOOD, 2019, 134
  • [34] COMBINATION OF IBRUTINIB AND ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF RELAPSING/ REFRACTORY MANTLE CELL LYMPHOMA (MCL)
    Ruella, M.
    Kenderian, S.
    Fraietta, J.
    Shestova, O.
    Qayyum, S.
    Zhang, Q.
    Liu, X.
    Maus, M.
    Lacey, S.
    Mato, A.
    Schuster, S.
    June, C.
    Wasik, M.
    Gill, S.
    HAEMATOLOGICA, 2015, 100 : 287 - 288
  • [35] Cirmtuzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib: Clinical Activity in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) from a Phase 1/2 Study
    Lee, Hun Ju
    Choi, Michael Y.
    Siddiqi, Tanya
    Wierda, William G.
    Barrientos, Jacqueline C.
    Lamanna, Nicole
    Goldenberg, Alec
    Isufi, Iris
    Tuscano, Joseph
    Subbiah, Suki
    Koff, Jean L.
    Leslie, Lori A.
    Chung, Gina G.
    Weihe, Elizabeth K.
    Ianopulos, Xen
    Breitmeyer, James B.
    Hsu, Frank J.
    Wang, Michael
    Jamieson, Catriona
    Kipps, Thomas J.
    BLOOD, 2020, 136
  • [36] Phase 1/2 Study of Cirmtuzumab and Ibrutinib in Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (07) : 13 - 14
  • [37] IBRUTINIB IN COMBINATION WITH RITUXIMAB AS FIRST-LINE TREATMENT FOR INDOLENT CLINICAL FORMS OF MANTLE CELL LYMPHOMA (MCL): RESULTS OF THE PHASE II IMCL-2015 GELTAMO TRIAL
    Gine, Soca E.
    De la Cruz, Vicente F.
    Jimenez, Ubieto A.
    Lopez, Jimenez J.
    Martin, Garcia-Sancho A.
    Terol, Castera M. J.
    Gonzalez, Barca E.
    De la Fuente, Burguera A.
    Casanova, Espinosa
    Marin-Niebla, A.
    Muntanola, Prat Ana
    Gonzalez, Lopez T. J.
    Aymerich, Gregorio M.
    Setoain, Perego X.
    Cortes-Romera, M.
    Rotger, Regi A.
    Medina, Herrera A.
    Garcia-Sanz, R.
    Campo, Guerri E.
    Lopez-Guillermo, A.
    HAEMATOLOGICA, 2020, 105 : 93 - 94
  • [38] MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial
    Jerkeman, Mats
    Kolstad, Arne
    Hutchings, Martin
    Pasanen, Annika
    Meriranta, Leo
    Niemann, Carsten Utoft
    Jorgensen, Rasmus Rask Kragh
    El-Galaly, Tarec Christoffer
    Riise, Jon
    Leppa, Sirpa
    Christensen, Jacob Haaber
    Sonnevi, Kristina
    Pedersen, Lone Bredo
    Wader, Karin Fahl
    Glimelius, Ingrid
    BLOOD ADVANCES, 2024, 8 (02) : 407 - 415
  • [39] Efficacy and Safety of Ibrutinib in Combination with Rituximab As Frontline Treatment for Indolent Clinical Forms of Mantle Cell Lymphoma (MCL): Preliminary Results of Geltamo IMCL-2015 Phase II Trial
    Gine, Eva
    De La Cruz, Maria de Fatima
    Grande, Carlos
    Jimenez, Javier Lopez
    Martin, Alejandro
    Terol, Maria Jose
    Gonzalez-Barca, Eva
    de la Fuente, Adolfo
    Niebla, Ana Marin
    Casanova, Maria
    Prat, Ana Muntanola
    Gonzalez-Lopez, Tomas Jose
    Aymerich, Marta
    Palacios, Lucia
    Setoain, Xavier
    Cortes-Romera, Montserrat
    Rotger, Amanda
    Medina, Alejandro
    Garcia-Sanz, Ramon
    Campo, Elias
    Lopez-Guillermo, Armando
    BLOOD, 2019, 134
  • [40] Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia
    Rogers, Kerry A.
    Huang, Ying
    Ruppert, Amy S.
    Awan, Farrukh T.
    Hoffman, Corrinne
    Maddocks, Kami J.
    Reid, Mark
    Woyach, Jennifer A.
    Whitlow, Thomas
    Jones, Jeffrey A.
    Byrd, John C.
    BLOOD, 2018, 132
12345